February 25, 2018 11:00 AM ET

Healthcare Equipment and Supplies

Company Overview of PharmaJet, Inc.

Company Overview

PharmaJet, Inc. develops and markets needle-free devices for the vaccine delivery sector. The company markets its products under the Stratis brand name. PharmaJet, Inc. was founded in 2005 and is based in Golden, Colorado.

400 Corporate Circle

Suite N

Golden, CO 80401

United States

Founded in 2005





Key Executives for PharmaJet, Inc.

Chairman and Chief Executive Officer
Age: 61
Chief Financial Officer
Chief Technology Officer
Vice Chairman and Chief Business Development Officer
Compensation as of Fiscal Year 2017.

PharmaJet, Inc. Key Developments

PharmaJet and Invectys partner in Phase II Clinical Trial of DNA Cancer Vaccine

PharmaJet announced that Invectys, a French-based biopharmaceutical company, received US FDA approval to proceed with a phase II clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system. Invectys previously announced the success of the phase I clinical trial of their INVAC-1, an immunotherapeutic DNA vaccine for the treatment of cancer. The company has performed studies to evaluate the PharmaJet Tropis® Needle-free injection system, both in human and animal clinical trials with no evidence of any safety concerns.

Pharmajet, Inc. Announces Clinical Study Results for mRNA Rabies Vaccine

PharmaJet, Inc. announced human clinical study of an mRNA rabies vaccine successfully showed immunogenicity when administered with their needle-free injection devices. A key finding was that the use of needle-free injection demonstrated successful immunogenicity of the vaccine, while needle-syringe failed to induce an adequate antibody response. Messenger RNA (mRNA) can be harnessed to carry data to instruct the human body to produce customized proteins as medicine to fight diseases. mRNA vaccines offer added advantages in that they are easily developed, inexpensive to produce, and efficiently scalable for manufacturing purposes.

PharmaJet Inc. Announces Availability of Quadrivalent and Trivalent Influenza Vaccine for Needle-Free Delivery for the 2017-18 Influenza Season

PharmaJet Inc. reported on August 29, 2017 the start of shipment of the quadrivalent and trivalent influenza vaccine for needle-free delivery for the 2017-2018 influenza season. The company's PharmaJet Stratis device for needle-free delivery system is now available and cleared by the US FDA for administration of inactivated influenza vaccines. This innovative Stratis device has US FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Private Placement
January 5, 2018
Private Placement
June 23, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PharmaJet, Inc., please visit www.pharmajet.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.